Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...

CDMO Rentschler Biopharma is signalling its intent to cut down cell and gene therapy operations by shutting down its UK ...

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics and headquartered in Switzerland, ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.

Cell and gene therapy presents a potential solution to these challenges, offering the possibility to treat diseases at a cellular or genetic level. However, as promising as these therapies are ...

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access ...

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...